Focused on developing innovative therapeutics for breast cancer and other breast conditions, this biopharmaceutical company has garnered investor attention for its pipeline of proprietary drug candidates. Its clinical-stage programs target unmet medical needs, making it a speculative yet closely watched player in the oncology space.
1 member of Congress has disclosed 1 trade in Atossa Therapeutics, Inc. (ATOS), a Healthcare company. The buy/sell breakdown shows 1 purchase versus 0 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2017-10-25 | Roger W. Marshall | buy | $1K – $15K |